AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine has received clinical trial approval from PRC's Center for Drug Evaluation (CDE), following its U.S. FDA clearance in March this year. The vaccine has demonstrated significantly stronger humoral and cellular immunity compared to international benchmark products.
AIM Vaccine's mRNA platform capabilities are once again in the spotlight. Fosun International Securities recently noted in a research report that AIM's mRNA shingles vaccine could challenge the existing market landscape with its potential for superior efficacy and safety.
Immunogenicity Indicators Significantly Outperform International Benchmarks
According to the announcement, preclinical trial results from third-party testing institutions demonstrate that AIM's mRNA shingles vaccine shows significantly higher specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescent antibody (FAMA) titers compared to internationally marketed recombinant subunit control vaccines.
Furthermore, there are currently no mRNA-based shingles vaccines approved for marketing globally. According to recently published industry references, the vaccination rate for shingles vaccines among PRC's target population is less than 1%, indicating enormous growth potential.
Fosun International Securities' research report analysis mentions that as PRC's first company to establish a complete mRNA vaccine R&D system, its technological approach successfully avoids existing shingles vaccine patent barriers, creating favorable conditions for entering the global market projected to reach US$23.9 billion annually.
mRNA Platform Capabilities Continue to Lead the Industry
The competition in mRNA technology platforms between domestic and international companies has reached intensity comparable to an arms race, with infectious disease and cancer vaccines being the key battlegrounds. AIM Vaccine leads the industry through breakthrough progress in infectious disease vaccines.
Fosun International Securities' research report released in late March pointed out that AIM Vaccine holds a leading position in PRC's mRNA vaccine field, having obtained 11 clinical approvals across 6 countries, including 2 FDA approvals in the U.S. Its platform technology has been validated by favorable safety and efficacy clinical data from over 10,000 subjects. This latest approval for its mRNA shingles vaccine in PRC further highlights the company's leading position in next-generation vaccine technology and rapid commercialization potential.
Some industry observers believe that if PRC companies can continue to overcome core patents, expand indications, and deepen international cooperation, mRNA technology may become a hallmark area for PRC's biopharmaceutical industry to achieve technological leapfrogging.
In this cutting-edge field, AIM Vaccine has not only secured clinical approvals in both PRC and the U.S. for its mRNA shingles vaccine and mRNA RSV vaccine, but also has its next-generation mRNA rabies vaccine and mRNA influenza vaccine in pre-IND review and preclinical studies respectively, demonstrating the platform's strong extensibility and laying a solid foundation for sustained development and market leadership.
As analyzed by multiple investment institutions, AIM Vaccine combines innovative technology, industry leadership, and growth potential, making it a highly attractive investment choice. They remain optimistic about the company's development prospects driven by industry recovery and new products, and believe its valuation has significant upside potential.
View original content:https://www.prnewswire.com/apac/news-releases/aim-vaccines-next-gen-mrna-shingles-vaccine-secures-clinical-approvals-in-both-prc-and-us-mrna-platform-advantages-shine-through-302458430.html
SOURCE AIM Vaccine
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength
GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences change rapidly and the market environment remains uncertain, how can companies precisely identify needs, execute efficiently, and continuously optimize their strategies? The Cyberway Product Innovation Platform empowers FMCG enterprises to achieve sustainable growth by providing powerful capabilities in pre-planning insight, in-process control, and post-launch analytics—ultimately enabling the development of exceptional product strength. Before: AI-Powered Foresight for Accurate Market Opportunity Detection AI Opportunity Discovery: Real-time industry data, user behavior, and competitor insights are captured to automatically identify blue ocean markets and unmet needs—fueling inspiration for new product planning. Accelerate Opportunity Capture: Shorten market research cycles and improve speed and accuracy of opportunity identification. AI-Driven Product Definition: Using opportunity and competitor analysis, combined with internal product knowledge bases, the system intelligently generates product concepts, optimizes configurations, and refines packaging and formulas. Agile Response: Ensure product design closely aligns with market needs and competition, allowing rapid focus on core value and improving product-market fit. End-to-End User Demand Management: A comprehensive demand management framework tracks records, statuses, and feedback, aggregating omnichannel voice of customer with AI to identify high-value & Accurate: By realizing and verifying demand in closed-loop cycles, continuously refine product performance, minimize resource waste, and pave the way for the next breakout product. During: Efficient Execution to Deliver Outstanding Products Scientific Project Management System: Integrates visual dashboards, all-in-one workbenches, and real-time notifications via Feishu, WeCom, and DingTalk for full project transparency and synchronized decision-making across teams. Core Value: Reduce communication overhead, improve collaboration efficiency, and prevent project delays. Standardized Project Workflow: Based on industry templates and task libraries, enabling tiered and structured project management tailored to channel requirements. Flexible Control: Guarantees high-quality delivery while allowing adaptive workflows, ensuring key tasks succeed the first time. Cross-Functional Online Collaboration: Integrates marketing, go-to-market, and product workflows to shorten timelines. Interlocked nodes require mutual confirmation to ensure stability and avoid cost waste. Key Feature: Enables synergistic cooperation across departments for performance greater than the sum of its parts. AI Marketing: Tracks competitor strategies and social trends in real time, dynamically generating targeted content and pricing strategies using internal knowledge. Efficient & Agile: Accelerates creative production and drives an integrated "strategy-content-pricing" engine for rapid market response. Online Knowledge Repository: A dedicated enterprise R&D knowledge base aggregating key data such as risk warnings, solutions, and technical documentation. Significant Boost: Empowers faster troubleshooting and prevents redundant errors in R&D. Comprehensive Quality Control System: Embeds IPD checkpoints and technical reviews to govern key milestones; incorporates risk management for prevention, monitoring, and post-analysis. Ultimate Goal: Ensure high-quality project delivery while minimizing potential risks. After: Data-Driven Innovation Strategy Optimization Project Review: Compare project baselines with actual execution to deeply analyze quality, timeline, and cost performance. Deeper Insights: Identify key factors that influence project success. Go-to-Market Tracking: Monitor GMV trends across e-commerce platforms, VOC on social media, and promotional campaign outcomes to pinpoint growth opportunities and risks, driving agile strategy iteration. Advanced Capabilities: Fuel product iteration and innovation, providing a core foundation for the next-generation breakout product. Data Asset Management: Leverages delivery data and gate review points to auto-update master product data, creating a unified view with field supplementation and relationship validation. Long-Term Value: Enables full-lifecycle product data management, enhancing both data quality and business utility. The Cyberway Product Innovation Collaboration Platform is a powerful enabler for FMCG enterprises to enhance product innovation with AI, reduce waste, shorten R&D cycles, and create market bestsellers. From ideation to launch and ongoing optimization, the platform empowers excellence at every stage—allowing businesses to stand out in an intensely competitive landscape. We look forward to partnering with more brands to explore new ways of innovation and co-create the next market blockbuster! Website: Email：Marketing@ View original content: SOURCE Cyberway Information Technology Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
The world's richest added $2B in 2025 — Use these 6 clever strategies to grow your own fortune fast
The 39th annual Forbes billionaire list is out, and it's a jaw-dropper. The number of billionaires has surged to 3,028, a record. Together, these individuals hold a staggering US$16.1 trillion in wealth, up US$2 trillion from last year. More than 100 Forbes reporters dove deep into financial data to assemble this list, including stocks, investments and cash flows, along with more eccentric billionaire purchases such as yachts, art collections and even dinosaur bones. The U.S. holds first place with 902 billionaires, followed by China and Hong Kong (516), and India (205). The wealthiest are led by Elon Musk, with US$342 billion, followed by Mark Zuckerberg at US$216 billion, and Jeff Bezos at US$215 billion. Rounding out the top 10 are heavyweights including Warren Buffett, Larry Ellison and LVMH's Bernard Arnault. In short, the billionaire game is booming. Want in on the action? You may want to take notes from the world's richest. According to Forbes senior editor Chase Peterson-Withorn, the rise in billionaire wealth isn't just about tech giants and luxury brands; it's about how much power these individuals hold. 'It's a great time to be a billionaire,' Peterson-Withorn recently told NPR's Morning Edition. To arrive at these figures, Forbes determines the annual list by tracking every asset, minus any debts. And if a billionaire doesn't spill the beans themselves, Forbes digs through legal filings, offshore accounts and leaks to get the scoop. This year, 288 new names have joined the ranks of the world's billionaires. Among them are celebrities such as Bruce Springsteen (US$1.2B), Arnold Schwarzenegger (US$1.1B) and Jerry Seinfeld (US$1.1B). Also on the list are crypto mogul Justin Sun (US$8.5B), along with AI entrepreneurs from companies including Anthropic, CoreWeave and DeepSeek. The food world is well-represented, with moguls behind popular chains such as Cava, Chipotle, Jersey Mike's and Zaxby's. Topping the list of newcomers is Marilyn Simons, who inherited a US$31 billion fortune following the passing of her husband, hedge fund legend Jim Simons, in 2024. But not every billionaire had a good year. Over 100 names dropped off the 2024 list, no longer rich enough to make the cut. Some notable exits include Lisa Su, CEO of semiconductor giant AMD, Sara Liu, co-founder of server company Supermicro and Nicholas Puech, heir to the Hermès luxury brand, who says his fortune has disappeared. "A lot of billionaires don't have great reputations these days," Peterson-Withorn said, "but on the other hand, they're more powerful than ever." There may be some backlash against the billionaires on the Forbes list, but that doesn't mean there aren't some lessons to be learned about investing from some of the world's wealthiest individuals. You don't need unlimited wealth to invest like a billionaire. The ultra-wealthy use strategy, smart decisions, as well as balancing risk and reward to get ahead. Here's how you can do the same. Ultra-high-net individuals spread their wealth across everything from stocks and real estate to private equity and bonds; in other words, diversifying is key. This reduces risk while increasing the chances for steady, long-term growth. For regular investors, diversifying with exchange-traded funds (ETFs) or mutual funds covering domestic and international markets is a good start. And don't forget bonds for stability during market ups and downs. Real estate is another billionaire favourite. While they may invest in expensive commercial or luxury residential properties, you can get in the game through real estate investment trusts (REITs) — here are the best in Canada. The super wealthy don't chase trends — they think decades ahead. Want to build wealth? Max out contributions to retirement accounts such as TFSAs and RRSPs. These tax-advantaged accounts let your money compound over time. While billionaires love high returns, they're pros at managing risk, and you can do the same by building an emergency fund. Having liquid cash in your account ensures you're not forced to sell investments during a market slump. A simple buffer can keep you secure while you wait for the market to bounce back. Wealthy investors leverage technology by using AI-powered predictions, algorithmic trading and cutting-edge tools to stay ahead. You don't need billions to tap into this power. Robo-advisors can help automate your portfolio management based on your goals to help you make smarter investment decisions — here are the best robo-advisors in Canada. Many high-net-worth individuals invest in alternative assets such as commodities and fine art to round out their portfolios. Commodities such as gold and silver can be hedges against inflation and market volatility. And while not highly liquid, collectibles, artwork or vintage cars can offer diversification and the potential for substantial returns. Investing like a billionaire isn't about having a billion-dollar portfolio. It's about following the basics, diversifying across asset classes and thinking long-term. Leverage technology, manage your risks and stay patient. Whether it's real estate, stocks or commodities, billionaire strategies can help set you on the path to financial success. Of course, always consult a financial advisor and do the proper research before you dive into any new investment. 1. Forbes: Forbes World's Billionaires List 2025: The Top 200, by Chase Peterson-Withorn (Apr 1, 2025) 2. NPR: More billionaires than ever ranked in Forbes' annual list. Here are the top 10, by A Martínez, Obed Manuel (Apr 1, 2025) This article provides information only and should not be construed as advice. It is provided without warranty of any kind. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
The Sad Case of The World's Youngest-Ever Alzheimer's Diagnosis
In 2023, neurologists at a memory clinic in China diagnosed a 19-year-old with what they believed to be Alzheimer's disease – making him the youngest person ever to be diagnosed with the condition. The teen first began experiencing memory decline around age 17, with symptoms worsening over time. Brain scans revealed shrinkage in the hippocampus, a region involved in memory, while his cerebrospinal fluid showed biomarkers consistent with Alzheimer's – the most common form of dementia. Although usually associated with older age, early-onset cases of Alzheimer's (those occurring in individuals under age 65) represent up to 10 percent of all diagnoses. Almost all Alzheimer's patients under the age of 30 can have their disease explained by pathological gene mutations, classifying them as having familial Alzheimer's disease (FAD). The younger a person is when they receive a diagnosis, the more likely it is caused by an inherited faulty gene. However, researchers at Beijing's Capital Medical University were unable to find any of the usual mutations responsible for the early onset of memory loss, nor any suspect genes, after conducting a genome-wide search. Before this diagnosis in China, the youngest patient with Alzheimer's was 21 years old. They carried the PSEN1 gene mutation, which causes abnormal proteins to build up in the brain, forming clumps of toxic plaques, a common feature of Alzheimer's. Cases like this one pose something of a mystery. None of the 19-year-old's family had a history of Alzheimer's or dementia, making it hard to categorize it as FAD, yet the teenager had no other diseases, infections, or head trauma that could explain his sudden cognitive decline either. Two years before being referred to the memory clinic, the teenage patient began struggling to focus in class. Reading also became difficult and his short-term memory declined. Oftentimes, he couldn't remember events from the day before, and he was always misplacing his belongings. Ultimately, the cognitive decline became so bad, the young man was unable to finish high school, although he could still live independently. A year after being referred to the memory clinic, he showed losses in immediate recall, short-delay recall after three minutes, and long-delay recall after 30 minutes. The patient's full-scale memory score was 82 percent lower than that of peers his own age, while his immediate memory score was 87 percent lower. Long-term follow-up is needed to support the young man's diagnosis, but his medical team said at the time the patient was "altering our understanding of the typical age of onset of AD." "The patient had very early-onset AD with no clear pathogenic mutations," neurologist Jianping Jia and colleagues wrote in their study, "which suggests that its pathogenesis still needs to be explored." The case study, published in February 2023, just goes to show that Alzheimer's doesn't follow a single pathway, and is much more complex than we thought, emerging via numerous avenues with varying effects. In a statement to the South China Morning Post, the neurologists who described the patient's case argued that future studies should focus on early-onset cases to further improve our understanding of memory loss. "Exploring the mysteries of young people with Alzheimer's disease may become one of the most challenging scientific questions of the future," they said. The study was published in the Journal of Alzheimer's Disease. An earlier version of this article was published in February 2023. Compound That Turns People Yellow Could Protect Against Malaria Scientists May Have Finally Figured Out How Bats Avoid Cancer 'Off Switch' in The Brain to Stop Binge Drinking Discovered in Mice
